Skip Navigation

Annals of Oncology 2007 18(9):1580-1582; doi:10.1093/annonc/mdm402
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wick, C
Right arrow Articles by Fey, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wick, C
Right arrow Articles by Fey, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

letters to the editor

The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry

The first 10% of the full text of this article appears below.

The pharmaceutical industry plays an important role in the development of new cancer treatments. Data from clinical phase I to III trials will, if convincing, eventually lead to the licensing of the drug. At that stage, and even before, companies embark on marketing and promotion of their new products [1, 2], by advertising in professional journals, through visits by drug company representatives, the organization of promotional meetings or sponsoring of continuous medical education. Finally, many drug companies maintain promotional mailing services to physicians to provide them with regular information, particularly on new drugs. Concern has been voiced that advertising may lead to uncritical and inappropriate prescribing of new drugs in clinical practice [3]. Articles prepared with drug company support have been shown to be more likely to report favourably on a drug of interest than . . . [Full Text of this Article]

C Wick1,2, M Egger1, S Trelle1, P Jüni1 and MF Fey2,*

1 Department of Social and Preventive Medicine
2 Department of Medical Oncology, University of Bern, Inselspital, Bern, Switzerland

* E-mail: martin.fey@insel.ch


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?